Jean Helmijr

Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes

Corine M. Beaufort, Jean Helmijr, Anna Piskorz et al. · PLoS ONE · 2014 · 414 citations · Full text

Medicine, Cancer Biology, Cell Biology +17

miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs

Muhammad Riaz, Marijn TM van Jaarsveld, Antoinette Hollestelle et al. · Breast Cancer Research · 2013 · 226 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions

Lisanne F. van Dessel, Nick Beije, Jean Helmijr et al. · Molecular Oncology · 2017 · 162 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases

Nick Beije, Jean Helmijr, Marjolein J.A. Weerts et al. · Molecular Oncology · 2016 · 75 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +17

Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen

Diana Ramirez-Ardila, Jean Helmijr, Maxime P. Look et al. · Breast Cancer Research and Treatment · 2013 · 56 citations

Medicine, Oncology, Pharmacology +15